Home › NDC Lookup › RxCUI directory › RxCUI 2059184

Amikacin liposomal 70.3 MG/ML Inhalation Suspension — RxCUI 2059184

RxNorm drug concept · Semantic clinical drug
RxCUI 2059184 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2059184
Official nameAmikacin liposomal 70.3 MG/ML Inhalation Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asamikacin liposomal 590 MG per 8.4 ML Inhalation Suspension; amikacin liposomal 590 MG in 8.4 ML Inhalation Suspension
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)597 prescriptions · 12 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Amikacin Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Amikacin is reserved for serious, hard-to-treat bacterial infections — the kind that either don't respond to standard antibiotics or are caused by bacteria that are resistant to ot...
  • Why am I getting amikacin instead of a regular oral antibiotic?
  • This is really important to stay on top of. The tricky thing is that hearing damage from amikacin often starts at high frequencies that you can't notice in everyday conversations....
  • How will I know if amikacin is affecting my hearing?
📖 Read our full Amikacin Injection guide →

🕸️ Concept Web — How Amikacin liposomal 70.3 MG/ML Inhalation Suspens... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Amikacin liposomal 70.3 MG/ML Inhalation Suspension RxCUI 2059184

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Amikacin 641
    • Amikacin liposomal 2059180
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Arikayce 2059185
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Amikacin Inhalation Suspension 2285804
    • Amikacin liposomal Inhalation Suspension 2648505
    • Amikacin Inhalant Product 2285812
    • Amikacin liposomal Inhalant Product 2661037
    • Amikacin Inhalation Suspension [Arikayce] 2285803
    • Amikacin liposomal Inhalation Suspension [Arikayce] 2657263
    • Arikayce Inhalant Product 2059188
    • Inhalation Suspension 2107948
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Amikacin liposomal 70.3 MG/ML SCDC · 2059181
  • Amikacin Inhalation Suspension SCDF · 2285804
  • Amikacin liposomal Inhalation Suspension SCDFP · 2648505
  • Amikacin Inhalant Product SCDG · 2285812
  • Amikacin liposomal Inhalant Product SCDGP · 2661037

Brand-Name Concepts

  • Amikacin liposomal 70.3 MG/ML Inhalation Suspension [Arikayce] SBD · 2059189
  • Amikacin liposomal 70.3 MG/ML [Arikayce] SBDC · 2059186
  • Amikacin Inhalation Suspension [Arikayce] SBDF · 2285803
  • Amikacin liposomal Inhalation Suspension [Arikayce] SBDFP · 2657263
  • Arikayce Inhalant Product SBDG · 2059188
  • Arikayce BN · 2059185

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2059184 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71558-0590-28 28 VIAL in 1 CARTON (71558-590-28) / 8.4 mL in 1 VIAL ARIKAYCE Insmed Incorporated 2018-10-12
Observed labelers: Insmed Incorporated (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.